Impact of Earlier Diagnosis in Cardiac ATTR Amyloidosis Over the Course of 20 Years
Adam Ioannou(MACOM (United States)), Marianna Fontana(Johnson & Johnson (United States)), Sharmananthan Ganesananthan(MACOM (United States)), Daniel Knight(MACOM (United States)), Aviva Petrie(Eastman Dental Hospital), Helen J. Lachmann(Royal Free London NHS Foundation Trust), Liza Chacko(The Royal Free Hospital), Ashutosh Wechelakar(MACOM (United States)), Gianfranco Sinagra(University of Trieste), Francesco Bandera(IRCCS Policlinico San Donato), Lucia Venneri(MACOM (United States)), Philip N. Hawkins(The Royal Free Hospital), Georgina E. Williams(MACOM (United States)), James Brown(MACOM (United States)), Charlotte Manisty(National Institutes of Health), Rishi Patel(MACOM (United States)), Julian D. Gillmore(Alnylam Pharmaceuticals (United States)), Ambra Masi(MACOM (United States)), Carol Whelan(Boston University), Sophie O’Beara(MACOM (United States)), Yousuf Razvi(MACOM (United States)), Aldostefano Porcari(University of Trieste), Muhammad U. Rauf(MACOM (United States)), Tushar Kotecha(Royal Society), Ana Martinez–Naharro(Children's Cancer and Leukaemia Group), Paolo Massa(MACOM (United States)), James Moon(Virginia Mason Medical Center)
Cited by 226
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
NALP3 Forms an IL-1β-Processing Inflammasome with Increased Activity in Muckle-Wells Autoinflammatory Disorder
|Immunity|2004|1.7k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k